Blog
RSS FeedPosted by Michael Wonder on 08 Mar 2016
Reducing drug waste could save billions of dollars
8 March 2016 - Given how expensive many cancer drugs are, it is alarming that the government, private insurers and patients ...
Posted by Michael Wonder on 08 Mar 2016
FDA accepts supplemental biologics license application for Keytruda (pembrolizumab) in advanced non-small cell lung cancer
8 March 2016 - The application is based on data from the Keynote-010 trial, which showed superior overall survival for ...
Posted by Michael Wonder on 06 Mar 2016
Imbruvica (ibrutinib) approved by U.S. FDA for the first-line treatment of chronic lymphocytic leukaemia
4 March 2016 - The approval is based on data from the randomized, multi-center, open-label Phase 3 Resonate-2 (PCYC-1115) trial, which ...
Posted by Michael Wonder on 03 Mar 2016
FDA approves new indication for Faslodex (fulvestrant)
2 March 2016 - The approval expands its use and offers additional option for women with HR+, HER2- metastatic breast ...
Posted by Michael Wonder on 27 Feb 2016
FDA approves new option for certain people with previously treated follicular lymphoma
26 February 2016 - the FDA has approved Gazyva (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyva alone as a ...
Posted by Michael Wonder on 26 Feb 2016
FDA approves new indication for Novartis drug Afinitor for progressive, non-functional gastro-intestinal and lung neuroendocrine tumors
26 February 2016 - Novartis today announced that the United States FDA approved Afinitor (everolimus) tablets for the treatment of adult ...
Posted by Michael Wonder on 25 Feb 2016
Pfizer receives expanded FDA approval for Ibrance (palbociclib) in HR+, HER2- metastatic breast cancer
19 February 2016 - Ibrance is now approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced ...
Posted by Michael Wonder on 28 Jan 2016
FDA approves first drug to show survival benefit in liposarcoma
28 January 2016 - The U.S. FDA today approved Halaven (eribulin mesylate) for the treatment of liposarcoma (a specific type of ...
Posted by Michael Wonder on 20 Jan 2016
From our perspective: Expedited oncology drug approvals
19 January 2016 - Richard Pazdur, M.D., Director of the FDA's Office of Hematology and Oncology Products, highlights some of his ...
Posted by Michael Wonder on 13 Dec 2015
FDA approves new oral therapy to treat ALK-positive lung cancer
11 December 2015 - The U.S. FDA today approved Alecensa (alectinib hydrochloride) to treat people with advanced (metastatic) ALK-positive non-small cell ...
Posted by Michael Wonder on 13 Dec 2015
FDA approves first emergency treatment for overdose of certain types of chemotherapy
11 December 2015 - The U.S. FDA today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who ...
Posted by Michael Wonder on 30 Nov 2015
FDA approves Empliciti, a new immune-stimulating therapy to treat multiple myeloma
30 November 2015 - Today the U.S. FDA granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat ...
Posted by Michael Wonder on 25 Nov 2015
FDA approves Portrazza to treat advanced squamous non-small cell lung cancer
24 November 2015 - The U.S. FDA today approved Portrazza (necitumumab) for use in combination with two forms of chemotherapy to ...
Posted by Michael Wonder on 23 Nov 2015
FDA approves Opdivo to treat advanced form of kidney cancer
23 November 2015 - The U.S. FDA today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a ...
Posted by Michael Wonder on 20 Nov 2015
FDA approves Ninlaro, new oral medication to treat multiple myeloma
20 November 2015 - Today the U.S. FDA granted approval for Ninlaro (ixazomib) for use in combination with two other therapies ...